Shattuck Labs (NASDAQ:STTK) versus MDxHealth (NASDAQ:MDXH) Financial Survey

Shattuck Labs (NASDAQ:STTK – Get Free Report) and MDxHealth (NASDAQ:MDXH – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Earnings and Valuation

This table compares Shattuck Labs and MDxHealth”s revenue, earnings per share and valuation.

MDxHealth has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Shattuck Labs and MDxHealth, as provided by MarketBeat.com.

Shattuck Labs currently has a consensus target price of $13.33, indicating a potential upside of 98.12%. MDxHealth has a consensus target price of $2.17, indicating a potential upside of 279.45%. Given MDxHealth’s higher probable upside, analysts plainly believe MDxHealth is more favorable than Shattuck Labs.

Insider and Institutional Ownership

58.7% of Shattuck Labs shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by insiders. Comparatively, 1.7% of MDxHealth shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Shattuck Labs has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.

Profitability

This table compares Shattuck Labs and MDxHealth’s net margins, return on equity and return on assets.

Summary

Shattuck Labs beats MDxHealth on 8 of the 15 factors compared between the two stocks.

About Shattuck Labs

(Get Free Report)

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

About MDxHealth

(Get Free Report)

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.